Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

872 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Nauck M, et al. Diabetologia. 1986 Jan;29(1):46-52. doi: 10.1007/BF02427280. Diabetologia. 1986. PMID: 3514343
Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F, Nauck MA, Ebert R, Cantor P, Hoffmann G, Choudhury AR, Schmidt WE, Creutzfeldt W. Baum F, et al. Among authors: nauck ma. Digestion. 1992;53(3-4):189-99. doi: 10.1159/000200994. Digestion. 1992. PMID: 1291406
Consequences of systemic venous drainage and denervation of heterotopic pancreatic transplants for insulin/C-peptide profiles in the basal state and after oral glucose.
Nauck M, Büsing M, Siegel EG, Talartschik J, Baartz A, Baartz T, Hopt UT, Becker HD, Creutzfeldt W. Nauck M, et al. Diabetologia. 1991 Aug;34 Suppl 1:S81-5. doi: 10.1007/BF00587626. Diabetologia. 1991. PMID: 1936703
Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W. Nauck M, et al. J Clin Endocrinol Metab. 1989 Sep;69(3):654-62. doi: 10.1210/jcem-69-3-654. J Clin Endocrinol Metab. 1989. PMID: 2668324
Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man.
Reimers J, Nauck M, Creutzfeldt W, Strietzel J, Ebert R, Cantor P, Hoffmann G. Reimers J, et al. Among authors: nauck m. Diabetologia. 1988 May;31(5):271-80. doi: 10.1007/BF00277407. Diabetologia. 1988. PMID: 3294066
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
Ritzel R, Orskov C, Holst JJ, Nauck MA. Ritzel R, et al. Among authors: nauck ma. Diabetologia. 1995 Jun;38(6):720-5. doi: 10.1007/BF00401846. Diabetologia. 1995. PMID: 7672496 Clinical Trial.
Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.
Nauck MA, Büsing M, Orskov C, Siegel EG, Talartschik J, Baartz A, Baartz T, Hopt UT, Becker HD, Creutzfeldt W. Nauck MA, et al. Acta Diabetol. 1993;30(1):39-45. doi: 10.1007/BF00572873. Acta Diabetol. 1993. PMID: 8329730
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Nauck MA, et al. Diabetologia. 1993 Aug;36(8):741-4. doi: 10.1007/BF00401145. Diabetologia. 1993. PMID: 8405741 Clinical Trial.
872 results
Jump to page
Feedback